Clinical trial
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell…
NCT00160069 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00160069 |
|---|---|
| Title | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer |
| Official title | Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non Small Cell Lung |
| Intervention type | Drug |
| Interventions | Sagopilone (BAY86-5302, ZK 219477) |
| Enrollment | 128 |
| Start date | Aug 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 4, 2014 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: